Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”
Summary
Currently, there are 4 leading marketed innovator drugs for the treatment of ITP of which the majority are thrombopoietin receptor agonist. Total market sales of ITP are expected to reach $3.3 Billion by 2026 and within this, there will be a significant acceptance of TPO-RA. Paras Biopharma’s unique technologies (Biomultifold®, Noblecleav® and Cytofold StructQuant®) facilitates achieving high productivity & quality of biologics.Paras Biopharmaceuticals has established its expertise in critical areas providing biologics CDMO, development of complex proteins from early stage to large scale, and the development of enzymes for medicinal and bioprocess purposes.Paras Biopharmaceuticals has a fully equipped biologics production facility in Finland for the manufacturing of recombinant therapeutic products in microbial systems. Other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.Paras Biopharmaceuticals has a Biologics CDMO Services pipeline www.parasbiopharma.com/microbial-biologics-cdmo.php and Biosimilars in Onco-Immunology, Urology, Osteoporosis and Rheumatoid Arthritis.